
How next-gen preclinical models can transform cell and gene therapies
David Vallerand, Director of Scientific Engagement for Crown Bioscience, examines the technologies advancing cell and gene therapy drug discovery. … Read More

David Vallerand, Director of Scientific Engagement for Crown Bioscience, examines the technologies advancing cell and gene therapy drug discovery. … Read More

Phacilitate’s 22nd Advanced Therapies Week (ATW) took place in San Diego on 9-12 February, bringing together industry stakeholders from around the world for to showcase progress in cell and gene therapies (CGT). From manufacturing bottlenecks and regulatory transparency to the rise of in vivo… Read More

Drug Discovery World speaks to key players in the cell and gene therapy sector to learn about the opportunities and challenges in this promising but difficult treatment area. … Read More

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More

What does the coming year hold for advanced therapies? Diana Turner asks industry leaders for their predictions for 2026. 2025 was a mixed year for cell and gene therapies (CGT) with some incredible breakthroughs, but also a withdrawal of many companies from their cell therapy programmes. Read More

News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW. This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology. The top stories: Combination therapy could slash melanoma mortality… Read More

ELRIG has announced Dr Stephen Ward and Dr Annarita Miccio as keynote speakers for its Cell and Gene Therapy event in March. The not-for-profit organisation aims to bring together leading scientists, economists and patient advocates to explore breakthroughs shaping the future of medicine. The programme, focussing on… Read More

The US Food and Drug Administration (FDA) said it is unable to approve the Atara Biotherapeutics’ off-the-shelf” allogeneic T-cell immunotherapy Ebvallo (tabelecleucel) based on the company’s Biologics License Application (BLA). The regulator ruled that the single arm ALLELE trial, which Atara’s says was previously confirmed by the… Read More

Diana Turner counts down the biggest DDW news stories of 2025. 10. First use of CAR-T therapy to treat ulcerative colitis In October, a team of physicians at the German Center for Immunotherapy at Erlangen University Hospital succeeded for the first time in treating a… Read More

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More

With topics as diverse as quantum computing, ion channel drug discovery and antisense oligonucleotides, these were DDW readers’ most-read articles of 2025. 10. We need international partnerships to get new cancer drugs into the clinic On International Clinical Trials Day, Lars Erwig, Director of the… Read More

News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW. This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells. The top stories: Scientists discover hidden molecular switch that… Read More

Charles River Laboratories has announced drug discovery companies will receive scientific and commercial expertise as part of the second cohort of its Cell and Gene Therapy Incubator Program (CIP). The CIP cohort includes six companies, four of which are advanced therapy developers (CureAge Therapeutics, InterAct Therapeutics, Jaan Biotherapeutics and Kopra Bio) and two enabling technology… Read More

The US Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). Waskyra is indicated for paediatric patients six months and older and adults with WAS who have a mutation in the WAS gene… Read More

Tighter budgets and company acquisitions have altered investment in the cell and gene therapy (CGT) sector, new analysis finds. According to a report from data and analytics company GlobalData, the CGT sector is transitioning as companies navigate a more selective and strategy-driven funding landscape. While venture… Read More

Cell and gene therapy CDMO eXmoor Pharma has partnered with Royal Free London NHS Foundation Trust to collaborate on the development and manufacturing of cell and gene therapies in the UK. The collaboration brings together eXmoor’s later-phase clinical manufacturing capabilities with the trust’s Cell and Vector Innovation Centre (CVIC), which… Read More